<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497727</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201903360 -N</org_study_id>
    <secondary_id>R01HL132448</secondary_id>
    <nct_id>NCT04497727</nct_id>
  </id_info>
  <brief_title>Gut Organoid Study</brief_title>
  <official_title>Gut Inflammation and Gut-Gut Microbiome Interactions in the Pathogenesis of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare basic properties of gut epithelia of hypertensive and normotensive&#xD;
      reference subjects. The study will determine if there are fundamental differences in the gut&#xD;
      epithelium in hypertension compared to normotension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Samples with DNA</measure>
    <time_frame>Visit 1 day</time_frame>
    <description>Biopsy specimens (formalin fixed and paraffin embedded) which are routinely obtained during the endoscopic procedure are retained according to legal requirements.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gut Inflammation</condition>
  <arm_group>
    <arm_group_label>Patients undergoing routine colonoscopy</arm_group_label>
    <description>Patients with and without hypertension who routinely undergo colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gene Expression</intervention_name>
    <description>Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination</description>
    <arm_group_label>Patients undergoing routine colonoscopy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During your scheduled colonoscopy, a maximum of 4 biopsies will be taken from your colon.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hypertensive and normotensive patients who routinely undergo scheduled elective colonoscopy&#xD;
        (for different, not selected reasons)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion/exclusion criteria for hypertension participants&#xD;
&#xD;
          -  Ages: 18-80 years old with a weight greater than or equal to 110 lbs&#xD;
&#xD;
          -  Diagnosis of hypertension or without hypertension for the reference cohort. 2017&#xD;
             ACC/AHA (American College of Cardiology/American Heart Association) definition for&#xD;
             hypertension (systolic blood pressure ≥130 mmHg and/or diastolic BP ≥80 mmHg) will be&#xD;
             used.&#xD;
&#xD;
          -  Scheduled elective colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertensive or reference individuals with history of autoimmune disease or other&#xD;
             chronic inflammatory conditions.&#xD;
&#xD;
          -  Pregnant or have been pregnant in the last six months.&#xD;
&#xD;
          -  Antibiotic treatment within two months of study enrollment&#xD;
&#xD;
          -  Currently taking a medication (e.g. antibiotic, anti-inflammatory agents,&#xD;
             glucocorticoids, other immune modulating medications, antacids or proton pump&#xD;
             inhibitor drugs like Prilosec) known to modify gut microbiota.&#xD;
&#xD;
          -  Unwilling to discontinue using probiotics for at least two weeks before scheduled&#xD;
             biopsy.&#xD;
&#xD;
          -  History of intestinal surgery, inflammatory bowel disease, celiac disease, lactose&#xD;
             intolerance, chronic pancreatitis or other malabsorption disorder.&#xD;
&#xD;
          -  History of blood transfusion within 4 weeks.&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, will be uncooperative or unable to&#xD;
             comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Pepine</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eileen Handberg</last_name>
    <phone>352-273-9082</phone>
    <email>handbem@medicine.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Handberg</last_name>
      <phone>352-273-9082</phone>
      <email>handbem@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Carl Pepine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

